Pharma Journalist -

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral…
Read More...

SMi Reports: The 2019 Respiratory Drug Delivery conference to host three interactive sessions this December. The Respiratory Drug Delivery, taking place in London on 5th-6th…
Read More...

Celltrion and Nan Fung Group announced the establishment of Vcell Healthcare Limited, a Joint Venture company between both parties. At the formation of the Joint Venture, Vcell…
Read More...

Aridis Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the…
Read More...

MilliporeSigma and the Broad Institute of MIT and Harvard announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for…
Read More...

Mallinckrodt plc and Silence Therapeutics plc announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the…
Read More...

"It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent demonstrate our commitment…
Read More...

Results from the INMARK study, a randomised, double-blind clinical trial of Ofev (nintedanib) vs. placebo (12 weeks) followed by an open label period (40 weeks) in patients with…
Read More...

Astellas Pharma Inc. and Frequency Therapeutics, Inc. announced that they have entered into an exclusive license agreement to develop and commercialize Frequency’s regenerative…
Read More...